GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Subscribe To Our Newsletter & Stay Updated